## Nicardipine and GW 8510 Combination / 8510 Viability**a** A 30 Nicardipine Concentration (µM) 20 **Excess over CDA** and Status of Dose 20 dCDAMon-dCDA 10 Observed Nicardipine 0 -10 0.48 EOCDA p-value = 0.436; $\rho$ = 0.08 GW 8510 Concentration (μM) 0.48 20 30 Estimate for Nicardipine and GW 8510 Viability **Tamoxifen and Atovaquone Combination** C and Atovaquone Viabilit 30 Tamoxifen Concentration ( $\mu$ M) 20 Excess over CDA 0 -5 -10 -15 -20 Observed Tamoxifen 0.48 EOCDA p-value = 6.72e-11; $\rho$ = 0 Atovaquone Concentration ( $\mu$ M) 0.48 Estimate for Tamoxifen and Atovaquone Viability **Tamoxifen and Mefloquine Combination** Ε Mefloquine Viability**1** 30 Tamoxifen Concentration ( $\mu$ M) 20 Excess over CDA 50 Status of Dose Observed Tamoxifen and 25 dCDAMon-dCDA 0.48 EQCDA p-value = 0.293; $\rho = 0$ Mefloquine Concentration ( $\mu$ M) 0.48 30 Estimate for Tamoxifen and Mefloquine Viability